Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Nephrotic syndrome

A watershed in the understanding of membranous nephropathy

Proof has at last been provided that idiopathic membranous nephropathy is caused by autoantibodies to proteins expressed by podocytes. The discovery that autoantibodies to the M-type secretory phospholipase A2 receptor were present in most individuals affected by the condition opens a new era for the management of membranous nephropathy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Schematic view of an M-type secretory phospholipase A2 receptor expressed on the surface of a podocyte.

References

  1. Heymann, W., Hackel, D. B., Harwood, S., Wilson, S. G. & Hunter, J. L. Production of nephrotic syndrome in rats by Freund's adjuvant and rat kidney suspensions. Proc. Soc. Exp. Biol. Med. 100, 660–664 (1959).

    Article  CAS  PubMed  Google Scholar 

  2. Beck, L. H. et al. M-type phospholypase A2 receptor as a target antigen in idiopathic membranous nephropathy N. Engl. J. Med. 361, 11–21 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ponticelli, C. Membranous nephropathy. J. Nephrol. 20, 268–287 (2007).

    CAS  PubMed  Google Scholar 

  4. Ronco, P. & Debiec, H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J. Am. Soc. Nephrol. 16, 1205–1213 (2005).

    Article  CAS  PubMed  Google Scholar 

  5. Evans, D. J. Pathogenesis of membranous glomerulonephritis. Lancet 1, 1143–1144 (1974).

    Article  CAS  PubMed  Google Scholar 

  6. Debiec, H. et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 364, 1252–1259 (2004).

    Article  CAS  PubMed  Google Scholar 

  7. Debiec, H. et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N. Engl. J. Med. 346, 2053–2060 (2002).

    Article  PubMed  Google Scholar 

  8. Ruggenenti, P. et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin. J. Am. Soc. Nephrol. 3, 1652–1659 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bomback, A. S. et al. Rituximab therapy for membranous nephropathy: a systematic review. Clin. J. Am. Soc. Nephrol. 4, 734–744 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

A. Rees is funded by an EU Marie Curie excellence Chair (MEXC-CT-2006-042742).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrew Rees.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rees, A., Kain, R. A watershed in the understanding of membranous nephropathy. Nat Rev Nephrol 5, 617–618 (2009). https://doi.org/10.1038/nrneph.2009.167

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2009.167

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing